Entelos to ID Most Effective Cardiovascular Disease Biomarkers for FNIH Biomarkers Consortium | GenomeWeb

NEW YORK (GenomeWeb News) – Entelos today said it has signed a contract with the Foundation for the National Institutes of Health Biomarkers Consortium to study and prioritize biomarkers of cardiovascular risk.

Under the terms of the contract, Entelos will use its Cardiovascular PhysioLab platform for the Biomarkers Consortium Atherosclerosis Project to perform computer simulations aimed at identifying those biomarkers that may be most effective at predicting cardiovascular disease and disease progression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.